<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887259</url>
  </required_header>
  <id_info>
    <org_study_id>LV-002-S042</org_study_id>
    <nct_id>NCT04887259</nct_id>
  </id_info>
  <brief_title>Trial With LAVA-051 in Patients With Relapsed/Refractory CD1d (Cluster of Differentiation (CD)1d)-Positive CLL, MM, AML</brief_title>
  <official_title>A Phase 1 and 2a Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients With Relapsed or Refractory CD1d-positive CLL, MM, or AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lava Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lava Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase 1/2a study to evaluate the safety and tolerability of LAVA-051 as&#xD;
      monotherapy in patients with relapsed or refractory CD1d-positive Chronic Lymphocytic&#xD;
      Leukemia (CLL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML).&#xD;
&#xD;
      Condition or disease: Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma (MM); Acute&#xD;
      Myeloid Leukemia (AML)&#xD;
&#xD;
      Intervention/ treatment; Biological - LAVA-051&#xD;
&#xD;
      Phase 1/2a&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/2a, first-in-human study to evaluate the safety, tolerability,&#xD;
      pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumor activity of&#xD;
      LAVA-051; a humanized gamma-delta bispecific T-cell engager (bsTCE) antibody, as monotherapy&#xD;
      in subjects with relapsed or refractory CD1d-positive CLL, MM, or AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 16, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>phase 1 sequential dose escalation cohorts phase 2 parallel disease specific cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1; Frequency of dose limiting toxicity (DLT)</measure>
    <time_frame>first 28 days of treatment</time_frame>
    <description>A DLT is defined as an adverse event that is unrelated to disease progression, intercurrent illness, or concomitant medications and is occurring during the first 28 days of treatment. These events will be classified according to the CTCAE v5.0; CRS will be evaluated according to the ASTCT consensus criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1; Safety; frequency and severity of Adverse Events using the CTCAE version 5.0 and ASTCT grading for CRS.</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>Frequency and severity of Adverse Events using the Common Terminology Criteria and grading for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) grading for Cytokine Release Syndrome (CRS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2; Safety; frequency and severity of Adverse Events using the CTCAE version 5.0 and ASTCT grading for CRS.</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>Frequency and severity of Adverse Events using the Common Terminology Criteria and grading for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) grading for Cytokine Release Syndrome (CRS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2; Number of patients who achieve an antitumor response</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>Antitumor response will be assessed for CLL according most recent International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guideline, for MM to the most recent International Myeloma Working Group (IMWG) criteria, for AML to the most recent European LeukemiaNet (ELN) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1; Number of patients who achieve an antitumor response</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>Antitumor response will be assessed for CLL according most recent International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guideline, for MM to the most recent International Myeloma Working Group (IMWG) criteria, for AML to the most recent European LeukemiaNet (ELN) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 &amp; part 2; Pharmacokinetics of LAVA-051, area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>first 28 days of treatment</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of LAVA-051 will be assessed in the patients treated with LAVA-051</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 &amp; part 2; Biomarkers, binding of LAVA-051 to Vγ9Vδ2-T cells (population of T cells that have a critical role in immune surveillance)</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>Binding of LAVA-051 to Vγ9Vδ2-T cells will be measured in serum and on tumor samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 &amp; part 2; Biomarkers, binding of LAVA-051 to CD1d positive tumor cells</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>Binding of LAVA-051 to CD1d positive tumor cells will be measured in serum and on tumor samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 &amp; part 2; Incidence of patients that develop anti-drug antibodies to LAVA-051</measure>
    <time_frame>Through study completion, 6 months</time_frame>
    <description>Potential development of antibodies (anti-drug antibodies) to LAVA-051 will be evaluated in plasma samples collected from all patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1 (dose escalation) LAVA-051 will be administered via intravenous infusion with dose escalation until an estimated therapeutic dose level has been reached.&#xD;
In part 2 (dose expansion) patients will receive LAVA-051 at the recommended phase 2 dose(s) established in part 1 of the study in disease specific cohorts for MM and/or CLL and/or AML</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LAVA-051</intervention_name>
    <description>In part 1 (dose escalation) LAVA-051 will be administered via intravenous infusion.&#xD;
In part 2 (dose expansion) LAVA-051 will be administered at the recommended phase 2 dose(s) and interval(s)</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for both Part 1 and Part 2 of the trial:&#xD;
&#xD;
          1. Patient must be 18 years of age inclusive or above, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          2. Confirmed tumor cell CD1d positivity/expression.&#xD;
&#xD;
          3. Patients with documented diagnosis of CLL, MM, or AML who have failed to respond to or&#xD;
             who have relapsed after prior therapy and are not amenable to standard treatments or&#xD;
             for whom no standard treatments are available.&#xD;
&#xD;
          4. Males or non-pregnant, non-breastfeeding females who are:&#xD;
&#xD;
               1. Surgically sterile&#xD;
&#xD;
               2. Female of childbearing potential with a negative pregnancy test prior to first&#xD;
                  dosing and compliant with a highly effective contraceptive regimen from signing&#xD;
                  of the informed consent form (ICF) through 90 days after the last Investigational&#xD;
                  Medicinal Product (IMP) administration.&#xD;
&#xD;
               3. Female, postmenopausal defined as continuous amenorrhea for at least 12&#xD;
                  consecutive months without an alternative medical cause and a serum&#xD;
                  follicle-stimulating hormone (FSH) measurement of &gt; 40 IU/L).&#xD;
&#xD;
               4. Male, compliant with an effective contraceptive regimen from signing of the ICF&#xD;
                  through 90 days after the last IMP administration.&#xD;
&#xD;
               5. Male, refraining from donating sperm following from signing of the ICF through 90&#xD;
                  days after the last IMP administration.&#xD;
&#xD;
          5. Predicted life-expectancy of ≥ 3 months.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          7. Adequate renal function ((estimated glomerular filtration rate (eGFR) per local&#xD;
             laboratory&gt; 40 mL/min/1.73m2)), hepatic function [(total bilirubin ≤ 2 times upper&#xD;
             limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase&#xD;
             (ALT) ≤ 3.0 times ULN] and hematological function (neutrophils ≥ 1 x109/L; platelet&#xD;
             count ≥ 75x109/L&#xD;
&#xD;
          8. Capable of giving signed and dated informed consent prior to initiation of any&#xD;
             trial-related procedure that is not considered Standard of Care which includes&#xD;
             compliance with the requirements and restrictions listed in the ICF and in the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior allogeneic bone marrow transplant as long as the patient still has active acute&#xD;
             or chronic graft versus host disease requiring &gt;10 mg prednisone or equivalent&#xD;
             corticosteroids.&#xD;
&#xD;
          2. Concomitant malignancies except carcinoma in situ, basal or squamous cell skin&#xD;
             carcinoma. Patients who had no evidence of disease from another primary cancer for 2&#xD;
             or more years are allowed to participate in the trial. Localized non-metastatic&#xD;
             prostate cancer, not requiring systemic treatment, and for which no local treatment is&#xD;
             planned, is allowed.&#xD;
&#xD;
          3. Uncontrolled or severe intercurrent medical condition.&#xD;
&#xD;
          4. Known uncontrolled central nervous system involvement.&#xD;
&#xD;
          5. A significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic,&#xD;
             metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the&#xD;
             investigator would adversely affect his/her participating in this trial.&#xD;
&#xD;
          6. Unstable cardiovascular function defined as: (a) symptomatic ischemia, or (b)&#xD;
             uncontrolled clinically significant conduction abnormalities (i.e., ventricular&#xD;
             tachycardia on antiarrhythmic agents are excluded; 1st degree atrioventricular block&#xD;
             or asymptomatic left anterior fascicular block/right bundle branch block (left&#xD;
             anterior fascicular block /right bundle branch block) will not be excluded), or (c)&#xD;
             congestive heart failure New York Heart Association Class ≥ 3, or (d) myocardial&#xD;
             infarction within 3 months.&#xD;
&#xD;
          7. Previous treatment with radiotherapy, immunotherapy, or chemotherapy in the 2 weeks&#xD;
             prior to initial IMP administration.&#xD;
&#xD;
          8. Previous treatment with biological therapy or with an investigational product in the 4&#xD;
             weeks prior to initial IMP administration.&#xD;
&#xD;
          9. Previous treatment of any systemic immunosuppressant within 2 weeks prior to initial&#xD;
             IMP administration, with the exception of systemic corticosteroid use up to oral dose&#xD;
             of 10 mg prednisolone daily (or equivalent for other steroids).&#xD;
&#xD;
         10. Previous treatment with live or live attenuated vaccines within 2 weeks prior to&#xD;
             initial IMP administration. Other (new) types of vaccines need to be evaluated as to&#xD;
             their mode of action.&#xD;
&#xD;
         11. Known non-CLL/MM/AML related pre-existing clinically relevant immunodeficiency&#xD;
             disorders.&#xD;
&#xD;
         12. Positive serological testing for human immunodeficiency virus (HIV) antibody,&#xD;
             hepatitis B surface antigen [HBsAg] and hepatitis B core antibody (anti-HBc) negative,&#xD;
             and hepatitis C virus antibody. Patients who are positive for anti-HBc or hepatitis C&#xD;
             antibody may be included if they have a negative Polymerase Chain Reaction (PCR)&#xD;
             within 6 weeks prior to initial IMP administration. Those who are PCR positive will be&#xD;
             excluded.&#xD;
&#xD;
         13. Known allergies, hypersensitivity, or intolerance to the excipients of the IMP.&#xD;
&#xD;
         14. Major surgery within 4 weeks of initial IMP administration or planned surgery during&#xD;
             the time the patient is expected to participate in the trial.&#xD;
&#xD;
         15. Known ongoing drug and alcohol abuse in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Winograd, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lava Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Holleman</last_name>
    <phone>+31 (0) 630 003 035</phone>
    <email>p.holleman@lavatherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Winograd, MD, PhD</last_name>
    <phone>+31 (0) 630 003 035</phone>
    <email>b.winograd@lavatherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Kater, MD, PhD</last_name>
      <email>a.p.kater@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels vd Donk, MD, PhD</last_name>
      <email>n.vandedonk@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemiek Broijl, MD, PhD</last_name>
      <email>a.broyl@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open-label</keyword>
  <keyword>phase 1 dose escalation</keyword>
  <keyword>phase 1 safety</keyword>
  <keyword>phase 2 proof of concept</keyword>
  <keyword>phase 2 safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

